Truist Securities Reiterates Buy Rating on Guardian Pharmacy Services

Truist Securities has reiterated its Buy rating on Guardian Pharmacy Services, Inc. (NYSE:GRDN), maintaining a price target of $47. This update was made by analyst David Macdonald on June 17, 2026. The stock is currently trading at around $42.42 per share.

Other Institutional Activity in Guardian Pharmacy Services

In the institutional scene, Driehaus Capital Management LLC increased its stake in Guardian Pharmacy Services by 82,646 shares, ending with 589,121 shares valued at about $22.19 million. On the other hand, Silvercrest Asset Management Group LLC reduced its holdings by 397,635 shares, now holding 374,946 shares worth approximately $14.12 million. Peregrine Capital Management LLC also trimmed its position by 19,453 shares, leaving it with 201,603 shares valued at $7.59 million. Meanwhile, Legato Capital Management LLC initiated a new position with 58,890 shares valued at $2.22 million.

Guardian Pharmacy Services Stock Snapshot

Shares of Guardian Pharmacy Services trade near $42.42. The company has a market cap of approximately $2.75 billion and a P/E ratio of 51.67, with a forward P/E of 31.95. The stock has a 52-week low of $19.30 and a high of $43.96, with a 50-day moving average of $38.44 and a 200-day moving average of $32.27. The company maintains a current ratio of 1.47 and a quick ratio of 1.1, with a debt-to-equity ratio of 17.72.

Recent Earnings

Guardian Pharmacy Services reported revenue of about $1.46 billion, reflecting a growth of 2.2%. The company's earnings per share (EPS) stand at $0.84, with a net margin of 3.65% and a return on equity (ROE) of 26.91%. The next earnings report is scheduled for August 10, 2026.

Analysts Set New Price Targets

On June 17, 2026, Truist Securities maintained its Buy rating on Guardian Pharmacy Services with a $47 price target. B of A Securities also maintained a Buy rating with the same target. Previously, Oppenheimer maintained a Buy rating with a $43 target on May 7, 2026. The consensus among analysts is a strong buy, with a mean target price of $44.17 based on six analyst opinions.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc. is a healthcare company based in Atlanta, Georgia. It provides pharmacy services and technology-enabled solutions to long-term healthcare facilities across the United States. The company serves residents in various facilities, including assisted living and behavioral health centers, using its advanced clinical and drug dispensing capabilities. Founded in 2003, Guardian Pharmacy Services employs about 3,600 people and is led by CEO Fred P. Burke.

Bottom Line

Truist Securities' reiteration of a Buy rating signals confidence in Guardian Pharmacy Services' performance, setting a price target of $47. Investors keep an eye on such ratings for insights into potential stock movements. Remember, 13F filings and analyst updates reflect past decisions and may not indicate current positions.